InMed Pharmaceuticals Common Stock Total Equity Over Time

INM Stock  USD 5.26  0.11  2.14%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out InMed Pharmaceuticals Performance and InMed Pharmaceuticals Correlation.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
  
As of the 15th of December 2024, Common Stock Total Equity is likely to drop to about 52.6 M.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
230.4
Revenue Per Share
0.603
Quarterly Revenue Growth
(0.45)
Return On Assets
(0.39)
Return On Equity
(0.72)
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Common Stock Total Equity Analysis

Compare InMed Pharmaceuticals and related stocks such as Quoin Pharmaceuticals, Allarity Therapeutics, and Kiromic Biopharma Common Stock Total Equity Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
ALLRKKKKKKKKKKKKK1.8 K1.6 K
SONN3013013015417252.1 K3105553701.5 K370370370426404
PALI260.1 K486.8 K681.9 K778.9 K877.9 K920.1 K110.3 K151.6 K182.1 K38.7 K173 K173 K173 K155.7 K147.9 K
TNXP5.5 K27.1 K43.2 KK11 K19 KKKKK206 K496 K496 K570.4 K598.9 K
PHIO10 K10 K16 K1000KK1000KK1000100010001000900855
ATNF1.4 K1.4 K1.4 K1.4 K1.4 K1.4 K1.4 K1.4 K1.4 K1.4 K2.6 K2.6 K2.6 KK2.2 K
NBY50 K286 K369 K446 K516 K35 K153 K154 K171 K279 K418 K418 K418 K480.7 K263.6 K
GOVX83 K16.4 K18.7 K23.8 K32 K31.9 K55.2 K106.7 K218.9 K3003.8 K3.8 K3.8 K3.5 K3.3 K

InMed Pharmaceuticals and related stocks such as Quoin Pharmaceuticals, Allarity Therapeutics, and Kiromic Biopharma Common Stock Total Equity description

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

My Equities

My Current Equities and Potential Positions

InMed Pharmaceuticals
INM
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationBritish Columbia; Canada
ExchangeNASDAQ Exchange
USD 5.26
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
Check out InMed Pharmaceuticals Performance and InMed Pharmaceuticals Correlation.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
InMed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of InMed Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of InMed Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...